Impact of interleukin-32α on T helper cell-related cytokines, transcription factors, and proliferation in patients with type 2 diabetes mellitus

References

• Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576(7785):51–60.
   PubMed Web of Science ®Google Scholar
• Kong L, Andrikopoulos S, MacIsaac RJ, et al. Role of the adaptive immune system in diabetic kidney disease. J Diabetes Investig. 2022;13(2):213–226.
   PubMed Web of Science ®Google Scholar
• Borzouei S, Sheikh V, Ghasemi M, et al. Anti-Inflammatory effect of combined sitagliptin and vitamin D3 on cytokines profile in patients with type 2 diabetes mellitus. J Interferon Cytokine Res. 2019;39(5):293–301.
   PubMed Web of Science ®Google Scholar
• Aass KR, Kastnes MH, Standal T. Molecular interactions and functions of IL-32. J Leukoc Biol. 2021;109(1):143–159.
   PubMed Web of Science ®Google Scholar
• Al-Shobaili HA, Rasheed Z. Elevated gene expression of interleukin-32 isoforms alpha, beta, gamma, and delta in the peripheral blood of chronic psoriatic patients. Diseases. 2018;6(1):21.
   PubMedGoogle Scholar
• Nold-Petry CA, Nold MF, Zepp JA, et al. IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci USA. 2009;106(10):3883–3888.
   PubMed Web of Science ®Google Scholar
• Yousif NG, Al-Amran FG, Hadi N, et al. Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine. 2013;61(1):223–227.
   PubMed Web of Science ®Google Scholar
• Na SJ, So SH, Lee KO, et al. Elevated serum level of interleukin-32α in the patients with myasthenia gravis. J Neurol. 2011;258(10):1865–1870.
   PubMed Web of Science ®Google Scholar
• Kang YH, Park MY, Yoon DY, et al. Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and bcl-2. Cancer Lett. 2012;318(2):226–233.
   PubMed Web of Science ®Google Scholar
• Yao Q, Wang B, Jia X, et al. Increased human interleukin-32 expression is related to disease activity of graves’ disease. Front Endocrinol. 2019;10:613.
   PubMed Web of Science ®Google Scholar
• Lin X, Yang L, Wang G, et al. Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells. Oncotarget. 2017;8(54):92841–92854.
   PubMedGoogle Scholar
• Saravia J, Chapman NM, Chi H. Helper T cell differentiation. Cell Mol Immunol. 2019;16(7):634–643.
   PubMed Web of Science ®Google Scholar
• Borzouei S, Moghimi H, Zamani A, et al. Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy. Hum Immunol. 2021;82(6):422–428.
   PubMed Web of Science ®Google Scholar
• Sheikh V, Zamani A, Mahabadi-Ashtiyani E, et al. Decreased regulatory function of CD4(+)CD25(+)CD45RA(+) T cells and impaired IL-2 signaling pathway in patients with type 2 diabetes mellitus. Scand J Immunol. 2018;88(4):e12711.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–324.
   PubMed Web of Science ®Google Scholar
• Alzamil H. Elevated serum TNF-α is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. J Obes. 2020;2020:5076858.
   PubMed Web of Science ®Google Scholar
• da Veiga GL, Della Nina Raffo MG, da Costa Aguiar Alves B, et al. NF-κB gene expression in peripheral blood and urine in early diagnosis of diabetic nephropathy – a liquid biopsy approach. Urine. 2019;1:24–28.
   Google Scholar
• Borzouei S, Mohamadtaheri M, Zamani A, et al. Reduced frequency and functional potency of CD49d(-) T regulatory cells in patients with newly diagnosed type 2 diabetes mellitus. Immunobiology. 2021;226(4):152113.
   PubMed Web of Science ®Google Scholar
• Moon YM, Yoon BY, Her YM, et al. IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther. 2012;14(6):R246.
   PubMed Web of Science ®Google Scholar
• Zeng C, Shi X, Zhang B, et al. The imbalance of Th17/Th1/tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med. 2012;90(2):175–186.
   PubMed Web of Science ®Google Scholar
• Öngöz Dede F, Gökmenoğlu C, Deveci ET, et al. Increased levels of interleukin-32 isoforms alpha, beta, gamma, and Delta in the gingival crevicular fluid and plasma of the patients with periodontitis. J Periodontal Res. 2021;56(1):83–92.
   PubMed Web of Science ®Google Scholar
• Techatanawat S, Surarit R, Chairatvit K, et al. Salivary and serum interleukin-17A and interleukin-18 levels in patients with type 2 diabetes mellitus with and without periodontitis. PLoS One. 2020;15(2):e0228921.
   PubMed Web of Science ®Google Scholar
• Kallionpää H, Somani J, Tuomela S, et al. Early detection of peripheral blood cell signature in children developing β-Cell autoimmunity at a young age. Diabetes. 2019;68(10):2024–2034.
   PubMed Web of Science ®Google Scholar
• Shoda H, Fujio K, Yamaguchi Y, et al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther. 2006;8(6):R166.
   PubMed Web of Science ®Google Scholar
• Mahabadi-Ashtiyani E, Sheikh V, Borzouei S, et al. The increased T helper cells proliferation and inflammatory responses in patients with type 2 diabetes mellitus is suppressed by sitagliptin and vitamin D3 in vitro. Inflamm Res. 2019;68(10):857–866.
   PubMed Web of Science ®Google Scholar
• Nold MF, Nold-Petry CA, Pott GB, et al. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol. 2008;181(1):557–565.
   PubMed Web of Science ®Google Scholar
• Li Y, Xie J, Xu X, et al. Inducible interleukin 32 (IL-32) exerts extensive antiviral function via selective stimulation of interferon λ1 (IFN-λ1). J Biol Chem. 2013;288(29):20927–20941.
   PubMed Web of Science ®Google Scholar
• Telikani Z, Sheikh V, Zamani A, et al. Effects of sitagliptin and vitamin D3 on T helper cell transcription factors and cytokine production in clinical subgroups of type 2 diabetes mellitus: highlights upregulation of FOXP3 and IL-37. Immunopharmacol Immunotoxicol. 2019;41(2):299–311.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tian J, Tian X, et al. Adipose tissue dendritic cells enhances inflammation by prompting the generation of Th17 cells. PLOS One. 2014;9(3):e92450.
   PubMed Web of Science ®Google Scholar
• Kang JW, Park YS, Lee DH, et al. Intracellular interaction of interleukin (IL)-32α with protein kinase Cε (PKCε) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells. J Biol Chem. 2012;287(42):35556–35564.
   PubMed Web of Science ®Google Scholar
• Jung MY, Son MH, Kim SH, et al. IL-32gamma induces the maturation of dendritic cells with Th1- and Th17-polarizing ability through enhanced IL-12 and IL-6 production. J Immunol. 2011;186(12):6848–6859.
   PubMed Web of Science ®Google Scholar
• Lao M, Li C, Li J, et al. Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: clinical features and associated factors. J Diabetes Investig. 2020;11(3):731–744.
   PubMed Web of Science ®Google Scholar
• Hernandez-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe. 2012;11(5):425–435.
   PubMed Web of Science ®Google Scholar
• Dotan I, Allez M, Nakazawa A, et al. Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-γ. Am J Physiol Gastrointest Liver Physiol. 2007;292(6):G1630–G1640.
   PubMed Web of Science ®Google Scholar
• Jakiela B, Kosałka J, Plutecka H, et al. Facilitated expansion of Th17 cells in lupus nephritis patients. Clin Exp Immunol. 2018;194(3):283–294.
   PubMed Web of Science ®Google Scholar
• Suga H, Sugaya M, Miyagaki T, et al. The role of IL-32 in cutaneous T-Cell lymphoma. J Invest Dermatol. 2014;134(5):1428–1435.
   PubMed Web of Science ®Google Scholar
• Blecker S, Park H, Katz SD. Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes. BMC Cardiovasc Disord. 2016;16:99.
   PubMed Web of Science ®Google Scholar